Cited by

• Perception of the risk of gastrointestinal adverse drug reactions with non-steroidal anti-inflammatory drugs (including coxibs): differences among general practitioners, gastroenterologists and rheumatologists.

  Montastuc JL, Bongard V, Lapeyre-Mestre M. Montastuc JL, et al. Eur J Clin Pharmacol. 2003 Nov;59(8-9):685-8. doi: 10.1007/s00228-003-0648-5. Epub 2003 Oct 11. Eur J Clin Pharmacol. 2003. PMID: 14556042
• Steady state pharmacokinetic profile of indomethacin in elderly patients and young volunteers.

  McElnay JC, Passmore AP, Crawford VL, McConnell JG, Taylor IC, Walker FS. McElnay JC, et al. Eur J Clin Pharmacol. 1992;43(1):77-80. doi: 10.1007/BF02280758. Eur J Clin Pharmacol. 1992. PMID: 1505614 Clinical Trial.
• Adverse drug events related to dosage forms and delivery systems.

  Uchegbu IF, Florence AT. Uchegbu IF, et al. Drug Saf. 1996 Jan;14(1):39-67. doi: 10.2165/00002018-199614010-00005. Drug Saf. 1996. PMID: 8713487 Review.
• Health-related quality of life assessments in osteoarthritis during NSAID treatment.

  de Bock GH, Hermans J, van Marwijk HW, Kaptein AA, Mulder JD. de Bock GH, et al. Pharm World Sci. 1996 Aug;18(4):130-6. doi: 10.1007/BF00717728. Pharm World Sci. 1996. PMID: 8873228 Clinical Trial.
• Misoprostol: pharmacoeconomics of its use as prophylaxis against gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs.

  Barradell LB, Whittington R, Benfield P. Barradell LB, et al. Pharmacoeconomics. 1993 Feb;3(2):140-71. doi: 10.2165/00019053-199303020-00007. Pharmacoeconomics. 1993. PMID: 10146962 Review.